APSR2026-170

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-002
P57
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1212209-46904-BADE, Andrea Lou DR-TB, BPAL-M RESEARCH_434922.pdf
Format: PDF Only
06. Tuberculosis
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Andrea Lou Bade * Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium Department of Internal Medicine Caloocan City Philippines
Acebuque Geramie - Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium Department of Internal Medicine Caloocan City Philippines
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Andrea Lou
Bade
algbade@gmail.com
+639175347148
31-40
Philippines
Original Research
The Clinical Profiles and Outcomes of Drug-Resistant Tuberculosis (DR-TB) Patients Treated with BPAL-M Regimen in a Tertiary Hospital in the Philippines
Maximum 25 words
Abstract Content
BACKGROUND: The Philippines, being known to have high number of tuberculosis cases and growing cases of Drug-resistant tuberculosis (DR-TB), holds a significant burden of the disease. With the revised guidelines on DR-TB treatment released in 2022, this study aims to determine the clinical profiles and outcomes of Drug-Resistant Tuberculosis (DR-TB) patients treated with BPAL-M regimen in Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium from January 2024 to January 2025.
METHODOLOGY: Total enumeration sampling was employed to include All adult DR-TB patients treated with BPAL-M regimen in Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium from January 2024 to January 2025. Retrospective records review of patient records was done the collected the following variables: demographics and clinical profile, treatment regimen, treatment success rate, and treatment outcomes.
RESULTS: Among the 19 patients, 52.63% were male (10 patients) and 47.37% were female (9 patients), with a mean age of 53 years (±1.5). The largest age group was 45–54 years, comprising 36.84% of the participants. The findings show that among the first-line anti-TB drugs, isoniazid (INH) had the highest resistance rate 52.6%. In terms of outcomes, 57.89% successfully completed their treatment and were classified as cured, reflecting a positive response to the regimen. However, 26.32% experienced treatment failure, suggesting that a significant portion did not respond adequately to the therapy.
CONCLUSION: These findings suggest that INH resistance is the most prevalent among the tested samples, indicating a potential trend toward monoresistance or the early stages of multidrug resistance in the studied TB cases. While the BPAL-M regimen shows promise in achieving high cure and completion rates, the noted treatment failures and losses to follow-up highlight areas for further monitoring and program improvement.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
BPALM, Drug-resistant tuberculosis
maximum 3 keywords and no abbreviations, separated by commas
N/A
287